Business Practice

Will the antibiotic apocalypse kill us all?

In times of political and social upheaval, maintaining our links across borders and working closely together is more important than ever.

With a no-deal Brexit still a real possibility, Merck continues to prepare for the worst case scenario.

Scientific careers are inherently unpredictable, but there are a number of steps we can take to be prepared.

Our animation explores the unique challenges a "no-deal" Brexit poses for the drug development and advanced therapy sectors.

We sit down with Nigel Theobald, Chief Executive, N4 Pharma. He tells us the story of his career and offers some advice for budding entrepreneurs.

Scouting for new leadership, prices hikes and successful acquisitions. What’s new for pharma in business?

Orphan drugs for rare diseases represent a significant unmet medical need for pharma, but commercialication can be tricky...

Nominations are now open for The Medicine Maker 2020 Power List.

John McCafferty, CEO of IONTAS, explains how his company’s work in mammalian cells could bring biopharmaceuticals to market faster.